Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 13, Issue 4, 2011, Pages 378-381

  Alam, M L ^a   Van Der Schueren, B J ^a   Ahren, B ^b   Wang, G C ^a   Swerdlow, N J ^a   Arias, S ^a   Bose, M ^a   Gorroochurn, P ^c   Teixeira, J ^a,d   McGinty, J ^a,d   Laferrere B ^a,d  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b LUND UNIVERSITY   (Sweden)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d College of Physicians and Surgeons ^*  (United States)

Author keywords

Dipeptidyl peptidase inhibitor; Gastric bypass; GLP 1; Weight loss

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

ADULT; BLOOD LEVEL; BODY MASS; BODY WEIGHT; CALORIC RESTRICTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVITY; HUMAN; LETTER; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; STOMACH BYPASS; WEIGHT REDUCTION;

EID: 79951868952     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01358.x     Document Type: Letter

References (12)

1. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737.
2. Morinigo R, Moize V, Musri M et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91: 1735-1740.
3. Laferrère B, Heshka S, Wang K et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007; 30: 1709-1716.
4. Laferrère B, Teixeira J, McGinty J et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 2479-2485.
5. Bose M, Machineni S, Olivan B et al. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring) 2010; 18: 1085-1091.
6. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 2009; 23: 443-452.
7. Rubino F, Forgione A, Cummings DE et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006; 244: 741-749.
8. Cummings BP, Strader AD, Stanhope KL et al. Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology 2010; 138: 2437-2446.
9. Carr RD, Larsen MO, Jelic K et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 2010; 95: 872-878.
10. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-688.
11. Ryskjaer J, Deacon CF, Carr RD et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155: 485-493.
12. Lugari R, Dei CA, Ugolotti D et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 2004; 36: 111-115.